JP2004535430A5 - - Google Patents

Download PDF

Info

Publication number
JP2004535430A5
JP2004535430A5 JP2003506572A JP2003506572A JP2004535430A5 JP 2004535430 A5 JP2004535430 A5 JP 2004535430A5 JP 2003506572 A JP2003506572 A JP 2003506572A JP 2003506572 A JP2003506572 A JP 2003506572A JP 2004535430 A5 JP2004535430 A5 JP 2004535430A5
Authority
JP
Japan
Prior art keywords
use according
modified pectin
medicament
patient
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003506572A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004535430A (ja
Filing date
Publication date
Priority claimed from US10/176,235 external-priority patent/US6680306B2/en
Application filed filed Critical
Publication of JP2004535430A publication Critical patent/JP2004535430A/ja
Publication of JP2004535430A5 publication Critical patent/JP2004535430A5/ja
Pending legal-status Critical Current

Links

JP2003506572A 2001-06-21 2002-06-21 癌治療の有効性を向上させる方法 Pending JP2004535430A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29999101P 2001-06-21 2001-06-21
US10/176,235 US6680306B2 (en) 2001-06-21 2002-06-20 Method for enhancing the effectiveness of cancer therapies
PCT/US2002/019885 WO2003000118A2 (en) 2001-06-21 2002-06-21 Method for enhancing the effectiveness of cancer therapies

Publications (2)

Publication Number Publication Date
JP2004535430A JP2004535430A (ja) 2004-11-25
JP2004535430A5 true JP2004535430A5 (enExample) 2006-01-05

Family

ID=26872020

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003506572A Pending JP2004535430A (ja) 2001-06-21 2002-06-21 癌治療の有効性を向上させる方法

Country Status (11)

Country Link
US (3) US6680306B2 (enExample)
EP (1) EP1406639A4 (enExample)
JP (1) JP2004535430A (enExample)
CN (1) CN100558367C (enExample)
AU (1) AU2002320140B2 (enExample)
BR (1) BR0210550A (enExample)
CA (1) CA2451841A1 (enExample)
CZ (1) CZ200487A3 (enExample)
IL (1) IL159461A0 (enExample)
MX (1) MXPA03012021A (enExample)
WO (1) WO2003000118A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2440555A1 (en) * 2001-03-14 2002-09-19 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
US6680306B2 (en) * 2001-06-21 2004-01-20 Glycogenesys, Inc. Method for enhancing the effectiveness of cancer therapies
US20030004132A1 (en) * 2001-06-22 2003-01-02 Yan Chang Method and material for treating immune diseases
US6890906B2 (en) 2001-11-21 2005-05-10 Glycogenesys, Inc. Method for controlling angiogenesis in animals
US20040121981A1 (en) * 2001-11-21 2004-06-24 Glycogenesys, Inc. Method for controlling angiogenesis in animals
US20040259816A1 (en) * 2002-10-01 2004-12-23 Pandol Stephen J. Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof
JP2006522163A (ja) * 2003-04-07 2006-09-28 グリコジェネシス， インク． ガレクチンアンタゴニストの組成物と使用
US20040223971A1 (en) * 2003-04-07 2004-11-11 Glycogenesys, Inc. Composition and uses of galectin antagonists
JP2007531697A (ja) * 2003-07-11 2007-11-08 プロ−ファーマシューティカルズ，インコーポレイティド 疎水性薬剤のデリバリーのための組成物と方法
DE10335236B3 (de) * 2003-08-01 2005-02-24 Drägerwerk AG Messsystem für die Bestimmung der Konzentration von Propofol (2,6-Diisopropylphenol) im Atemstrom
US20050053664A1 (en) * 2003-09-08 2005-03-10 Eliezer Zomer Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
WO2005037293A1 (en) * 2003-10-16 2005-04-28 Univ Monash Immunomodulating compositions and uses therefor
US20050282773A1 (en) * 2004-01-14 2005-12-22 Pro-Pharmaceuticals, Inc. Modified polysaccharides in combination with anti-cancer drugs for enhanced treatment of cancer
EP1718146A2 (en) * 2004-02-13 2006-11-08 Pro-Pharmaceuticals, Inc. Compositions and methods used to treat acne and candida
EP1765874A1 (en) 2004-03-26 2007-03-28 Glycogenesys, Inc. Modified pectins, compositions and methods related thereto
WO2006020027A1 (en) * 2004-07-14 2006-02-23 Glycogenesys, Inc. Composition and method for treating hyperproliferative diseases
WO2006017417A2 (en) * 2004-08-02 2006-02-16 Pro-Pharmaceuticals, Inc. Compositions and methods for the enhancement of chemotherapy with microbial cytotoxins
CN101146553A (zh) * 2005-03-23 2008-03-19 辉瑞产品公司 用于治疗癌症的抗-ctla4抗体和吲哚酮组合治疗
US8221803B1 (en) 2007-06-25 2012-07-17 OncoNatural Solutions, Inc. Composition for prostate health
WO2009018447A2 (en) * 2007-07-31 2009-02-05 New York University Diagnostic and treatment methods for characterizing bacterial microbiota in skin conditions
US8968740B2 (en) 2009-11-13 2015-03-03 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
RU2545859C1 (ru) * 2011-12-08 2015-04-10 Исаак ЭЛИАС Уменьшение уровней галектина-3 посредством плазмафереза
AU2012363033B2 (en) * 2011-12-28 2016-06-02 Galectin Therapeutics, Inc. Composition of novel carbohydrate drug for treatment of human diseases
WO2013152313A1 (en) * 2012-04-05 2013-10-10 The Regents Of The University Of California Compositions and methods for treating cancer and diseases and conditions responsive to growth factor inhibition
WO2013184892A1 (en) 2012-06-06 2013-12-12 Galectin Therapeutics, Inc. Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase
WO2014043708A1 (en) 2012-09-17 2014-03-20 Traber Peter G Method for enhancing specific immunotherapies in cancer treatment
ES2698101T3 (es) 2012-10-10 2019-01-31 Galectin Therapeutics Inc Compuestos de carbohidrato con restos de galactosa para el tratamiento de la nefropatía diabética y trastornos asociados
WO2014130648A1 (en) 2013-02-20 2014-08-28 Galectin Therapeutics, Inc. Method for treatment of pulmonary fibrosis
WO2015071910A1 (en) 2013-11-17 2015-05-21 Rdd Pharma Ltd. Methods for treating radiation induced gastrointestinal tract injury
CA3031691A1 (en) 2016-09-13 2018-03-22 Rasna Research Inc. Dactinomycin compositions and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia
AU2018265571B2 (en) 2017-05-12 2022-09-29 Galectin Sciences, Llc Compounds for the prevention and treatment of diseases and the use thereof
KR20210108414A (ko) 2018-12-25 2021-09-02 솔-겔 테크놀로지스 리미티드 Egfr 억제제를 포함하는 조성물에 의한 피부 장애 치료

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US107222A (en) * 1870-09-13 Improvement in machines for tenoning window-sash
US5490991A (en) 1986-07-03 1996-02-13 Advanced Magnetics, Inc. Directed delivery of radioprotectants using a receptor specific carrier
US5843442A (en) 1990-10-22 1998-12-01 Corvas International, Inc. Blood coagulation protein antagonists and uses therefor
US5639737A (en) 1991-11-04 1997-06-17 Co Enzyme Technology Ltd. Method and compositions for treating malignant tumors and inhibiting growth and metastases of malignant tumors
US20020107222A1 (en) 1993-03-01 2002-08-08 David Platt Modified polysaccharides for treatment of cancer
US5490911A (en) * 1993-11-26 1996-02-13 The United States Of America As Represented By The Department Of Energy Reactive multilayer synthesis of hard ceramic foils and films
US5498702A (en) * 1993-12-16 1996-03-12 California Natural Products Treated pectinic acid process and product
US5834442A (en) * 1994-07-07 1998-11-10 Barbara Ann Karmanos Cancer Institute Method for inhibiting cancer metastasis by oral administration of soluble modified citrus pectin
US5681923A (en) 1995-10-06 1997-10-28 Platt; David Tumor derived carbohydrate binding protein
WO1997033593A1 (en) * 1996-03-15 1997-09-18 Takara Shuzo Co., Ltd. A product of heat treatment of uronic acid, food, drink or drug including the product
US5831052A (en) * 1997-05-07 1998-11-03 Incyte Pharmaceuticals, Inc. New human translocation associated protein
CN1282218A (zh) * 1997-10-15 2001-01-31 波拉克斯生物药品 使用砷化合物治疗原发性及转移性肿瘤疾病的组合物及方法
US6258383B1 (en) * 1998-08-14 2001-07-10 Lactoferrin Products Company Dietary supplement combining colostrum and lactoferrin in a mucosal delivery format
US6500807B1 (en) * 1999-02-02 2002-12-31 Safescience, Inc. Modified pectin and nucleic acid composition
US6274566B1 (en) * 1999-02-23 2001-08-14 Econugenics, Inc. Methods for treating mammals with modified alginates and pectins
EP1363673A2 (en) * 2000-09-25 2003-11-26 Pro-Pharmaceuticals, Inc. Compositions for reducing side effects in chemotherapeutic treatments
US20020104222A1 (en) * 2001-02-06 2002-08-08 Jay Larry Dean Knife for removing the hide of an animal and method therefor
US6645946B1 (en) * 2001-03-27 2003-11-11 Pro-Pharmaceuticals, Inc. Delivery of a therapeutic agent in a formulation for reduced toxicity
ES2376739T3 (es) * 2001-03-27 2012-03-16 Galectin Therapeutics Inc. Administración conjunta de un polisacárido con un agente quimioterapéutico para el tratamiento del cáncer
US6982255B2 (en) * 2001-03-27 2006-01-03 Anatole Klyosov Delivery of a therapeutic agent in a formulation for reduced toxicity
US6914055B2 (en) * 2001-03-27 2005-07-05 Anatole Klyosov Delivery of a therapeutic agent in a formulation for reduced toxicity
US6680306B2 (en) * 2001-06-21 2004-01-20 Glycogenesys, Inc. Method for enhancing the effectiveness of cancer therapies
US20040223971A1 (en) * 2003-04-07 2004-11-11 Glycogenesys, Inc. Composition and uses of galectin antagonists
WO2006020027A1 (en) * 2004-07-14 2006-02-23 Glycogenesys, Inc. Composition and method for treating hyperproliferative diseases

Similar Documents

Publication Publication Date Title
US8735373B2 (en) Glycosaminoglycan oral use and compositions
JP5425216B2 (ja) 癒着防止用組成物
WO2000066125A1 (en) Method for treating cancer using camptothecin derivatives and 5-fluorouracil
SI2099462T1 (sl) Farmacevtski pripravek za zdravljenje vnetnih bolezni urogenitalnega trakta
CA2337152C (en) Pharmaceutical composition intended in particular for the prevention and the treatment of radiomucositis and chemomucositis
CA2590159A1 (en) Regimens for intra-articular viscosupplementation
JP2003522796A5 (enExample)
WO2019155389A1 (en) An aqueous mucoadhesive and bioadhesive composition for the treatment
NZ553390A (en) Nutritional composition comprising indigestible oligosaccharides
US20080182816A1 (en) Methods for preparing a novel family of polysaccharride prodrugs for colonic delivery
JP2011037849A (ja) 消化性潰瘍及び十二指腸潰瘍の治療及び予防に使用されるヒアルロン酸混合物
WO2004098564A3 (en) Biodegradable nanoparticles comprising an aminoglycoside and a polymer like a polysaccharide
JP2004536825A5 (enExample)
WO2008106721A1 (en) Compositions and methods for delivery of anti-cancer agents
WO2005025501A3 (en) Co-administration of polysaccharide with a chemotherapeutic agent for the treatment of cancer
TWI516269B (zh) 使用於炎症性腸疾病（ｉｂｄ）治療和預防之透明質酸混合物
US9241953B2 (en) Glycosaminoglycan oral use and compositions
CA2519797A1 (en) Low molecular weight hyaluronic acid for the treatment of nerve damage
TW201124142A (en) Hypersulfated disaccharide formulations
WO2007064448A3 (en) Cancer treatment using fts and 2-deoxyglucose
CA2516318A1 (en) Use of glycosaminoglycans such as heparin for the treatment of respiratory disorders such as copd
Singh et al. Chitosan hydrogel: Its applications in medicine and dentistry
EA009209B1 (ru) Фармацевтическая композиция, содержащая цинк-гиалуронановый комплекс, предназначенная для лечения рассеянного склероза
CA2234936A1 (en) Composition for and treatment of inflammatory bowel disease by colon administration of n-acetylglucosamine
CA2485449A1 (en) Method for preventing mucositis during cancer therapy